CONRAY 400 Drug Patent Profile
✉ Email this page to a colleague
When do Conray 400 patents expire, and when can generic versions of Conray 400 launch?
Conray 400 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in CONRAY 400 is iothalamate sodium. There is one drug master file entry for this compound. Additional details are available on the iothalamate sodium profile page.
Summary for CONRAY 400
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Patent Applications: | 600 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CONRAY 400 at DailyMed |
US Patents and Regulatory Information for CONRAY 400
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mallinckrodt | CONRAY 400 | iothalamate sodium | INJECTABLE;INJECTION | 014295-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |